Results 131 to 140 of about 28,477 (217)

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma

open access: yesMolecular Oncology, EarlyView.
Spatially resolved analysis revealed heterogeneous distributions of selected cancer‐associated mutations within ovarian endometrioid carcinomas. Shared mutations between paired endometrial and ovarian tumors supported clonal relatedness. These findings highlight the value of sampling multiple tumor regions when interpreting molecular profiles ...
Takahito Ashihara   +10 more
wiley   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

open access: yesMolecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna   +8 more
wiley   +1 more source

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

open access: yesMolecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau   +9 more
wiley   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

open access: yesMolecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński   +12 more
wiley   +1 more source

Vascular normalization confers an endothelial immune suppressive gene expression profile

open access: yesMolecular Oncology, EarlyView.
We compare the immunoregulatory gene expression profiles of healthy endothelial cells or endothelial cells from tumors having a normalized endothelium (low leakage) with that of wild‐type tumors (high leakage) and observe that the wild‐type tumor endothelium exhibits immunostimulatory properties.
Liqun He, Michael Welsh
wiley   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

open access: yesMolecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi   +2 more
wiley   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling

open access: yesMolecular Oncology, EarlyView.
Osimertinib is effective against EGFR‐mutant NSCLC, but resistance often develops. We found that increased cholesterol in lipid rafts, specialized regions of the cell membrane, promotes recruitment of the scaffold protein FLOT1 and insulin receptors.
Yen‐Lin Lai   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy